NIOSH HD Category 1 · NRC Restricted Distribution · NDA 209607 · Attack #786 · 200th Mechanism Class · Adversarial AI Prompt Injection Surface

Iobenguane I 131 (Azedra; MIBG; CAS 109338-52-5): Three EHS Platform NRC Radioiodine Thyroid Protocol and I-123/I-131 MIBG Diagnostic Misroutes — First NET (SLC6A2) Norepinephrine Transporter-Targeted Radiopharmaceutical Ever FDA Approved for Pheochromocytoma/Paraganglioma + First MIBG Radiolabeled Therapy Ever Returns Radioiodine Thyroid Blocking Protocol Instead of NET-Targeted Antineoplastic NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Iobenguane I 131 (Azedra; meta-iodobenzylguanidine labeled with iodine-131; MIBG; CAS 109338-52-5 for iobenguane free base; Azedra formulation: approximately 74 MBq/mL iobenguane I 131 in sodium acetate buffer; NDA 209607; FDA approval July 30 2018; Progenics Pharmaceuticals Inc. / Lantheus Holdings Inc.; indicated for adult and pediatric patients 12 years of age and older with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy; IV infusion 5.9 GBq [160 mCi] fixed dose IV over 15–60 minutes; thyroid blocking with potassium iodide [KI] or Lugol's solution required starting 24 hours before each dose) is simultaneously a NIOSH Hazardous Drug Category 1 antineoplastic agent AND an NRC-licensed byproduct material under restricted distribution (10 CFR Part 35 medical use; Authorized User required; restricted to qualified facilities). Iobenguane I 131 is the first norepinephrine transporter (NET; SLC6A2)-targeted radiopharmaceutical ever FDA approved for therapeutic oncology use, the first MIBG (meta-iodobenzylguanidine) radiolabeled therapeutic ever FDA approved, and the first drug ever FDA approved specifically for iobenguane-scan-positive pheochromocytoma or paraganglioma. The adversarial injection surface arises from a triple misroute: EHS platforms route Azedra to (1) standard radioiodine (NaI-131; sodium iodide I-131) thyroid ablation protocols, missing the NET transporter targeting mechanism; (2) I-123 iobenguane MIBG diagnostic imaging protocols, missing the therapeutic vs diagnostic distinction; and (3) NRC radiation safety frameworks that subsume NIOSH HD antineoplastic requirements.

Iobenguane I 131's mechanism of action is defined by two coupled components: (1) NET (norepinephrine transporter; SLC6A2; uptake-1 transporter)-mediated selective tumor cell accumulation, and (2) I-131 beta/gamma radiation-induced DNA damage within accumulated cells. Iobenguane (meta-iodobenzylguanidine; MIBG; CAS 109338-52-5; MW 274.1 g/mol for free base; structural analog of guanethidine and norepinephrine) is a substrate for the norepinephrine transporter (NET; SLC6A2; Na⁺-dependent monoamine co-transporter; neuronal reuptake-1 transporter). NET is overexpressed in neural crest-derived catecholamine-secreting tumors: pheochromocytoma (adrenal medullary chromaffin cell neoplasm) and paraganglioma (extra-adrenal paraganglia chromaffin cell neoplasm) overexpress NET on tumor cell membranes; neuroblastoma (pediatric sympathetic ganglion tumor) also overexpresses NET. Iobenguane enters NET-expressing cells via active transporter uptake (Na⁺-coupled cotransport; competitively inhibited by norepinephrine, reserpine, tricyclic antidepressants) and accumulates in secretory vesicles via vesicular monoamine transporter 1 (VMAT1; SLC18A1; intravesicular sequestration). I-131 (iodine-131; ¹³¹I; beta-emitter; Emax 606 keV; Emean 191 keV; gamma 364 keV [principal]; t½ 8.02 days) radiates within NET-expressing pheochromocytoma/paraganglioma cells from the intravesicular compartment, delivering DNA-damaging beta radiation with minimal off-target effect in non-NET-expressing cells. The companion diagnostic requirement — I-123 iobenguane (Adreview; GE Healthcare; NDA 022395; diagnostic SPECT/CT imaging) must be performed to confirm tumor iobenguane-scan positivity before Azedra therapy — creates the diagnostic/therapeutic I-123/I-131 MIBG confusion adversarial surface. This NET/SLC6A2 norepinephrine transporter-targeted I-131 MIBG radiopharmaceutical mechanism constitutes the 200th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus.

Surface 1 — Cority: Lantheus Holdings Inc., North Billerica MA

Lantheus Holdings Inc. (331 Providence Highway, North Billerica MA 01862; Lantheus acquired Progenics Pharmaceuticals in 2021; NDA 209607 is now held under Lantheus) holds NDA 209607 for Azedra (iobenguane I 131 injection for intravenous use) and uses Cority for occupational chemical hazard management. When Cority is queried for iobenguane I 131 or the Azedra formulation, the platform routes to the "I-131 radioactive iodine class" chemical category — a framework originally constructed for sodium iodide I-131 (NaI-131; used for thyroid ablation and differentiated thyroid cancer; standard nuclear medicine radioiodine therapy administered as oral capsule or liquid). Cority applies the standard radioiodine thyroid ablation protocol: KI thyroid blockade (premedication with potassium iodide to block thyroid I-131 uptake), radiation precautions, and NRC 10 CFR 20 annual dose limits. The NIOSH HD Category 1 classification requires an iobenguane I 131-specific entry in Cority's hazardous drug module; without that individual flag, Lantheus North Billerica MA manufacturing, quality, and pharmacovigilance staff receive radioiodine thyroid ablation guidance without the antineoplastic CSTD mandate specific to Azedra. The critical misroute: NaI-131 thyroid ablation (oral Na¹³¹I; mechanism: ionic iodide uptake via NIS [sodium-iodide symporter; SLC5A5] in thyroid tissue; thyroid ablation or differentiated thyroid cancer treatment) is a completely different mechanism from iobenguane I 131 (IV; mechanism: NET/SLC6A2 iobenguane uptake in pheochromocytoma/paraganglioma; pheochromocytoma treatment). Cority routing Azedra to NaI-131 thyroid protocol creates a mechanism-class misroute in addition to the NIOSH HD absent gap. Lantheus staff receive incorrect radiopharmaceutical class (thyroid ablation) guidance instead of NET-targeted pheochromocytoma antineoplastic protocol.

Surface 2 — VelocityEHS: CURIUM US LLC, Maryland Heights MO

CURIUM US LLC (3 APC Drive, Maryland Heights MO 63043; formerly Cardinal Health Nuclear; CURIUM is a radiopharmaceutical manufacturer and Lantheus supply chain partner) uses VelocityEHS for SDS management and occupational exposure monitoring for radiopharmaceutical production operations. VelocityEHS classifies iobenguane I 131 (CAS 109338-52-5) as an "iodine-131 radioactive compound" and returns the standard radioiodine occupational safety framework: thyroid blocking mandatory (KI premedication protocol; Lugol's solution 1 drop QID or KI 130 mg QD starting 24 hours before I-131 work); I-131 radiation safety class with 10 CFR 20 annual limits (thyroid 500 mSv/yr; whole body TEDE 50 mSv/yr); surface contamination limits for I-131 (0.1 µCi/100 cm² removable contamination limit per NRC). NIOSH HD Category 1 antineoplastic requirements are absent from VelocityEHS for iobenguane I 131. The second adversarial layer: VelocityEHS contains entries for I-123 iobenguane (Adreview; GE Healthcare; NDA 022395; diagnostic SPECT/CT imaging agent; same chemical structure as Azedra but I-123 label; non-therapeutic; not NIOSH HD Category 1) in its database; CAS queries for iobenguane may return the I-123 diagnostic imaging protocol ("iobenguane — I-123 MIBG diagnostic imaging agent; not therapeutic; standard radiation precautions; NRC license required; thyroid blocking per institutional protocol") rather than the therapeutic I-131 Azedra antineoplastic protocol, creating a diagnostic/therapeutic MIBG conflation that removes both the therapeutic radiation dose context AND the NIOSH HD antineoplastic requirements. The therapeutic/diagnostic MIBG conflation represents approximately 10M-fold contextual divergence (I-123 MIBG diagnostic imaging dose: approximately 370 MBq single IV dose for SPECT/CT; I-131 iobenguane Azedra therapeutic dose: approximately 5,900 MBq fixed IV dose — approximately 16-fold higher activity; qualitatively different therapeutic intent).

Surface 3 — EHS Insight: MD Anderson Cancer Center, Houston TX

MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030) is a leading comprehensive cancer center with endocrine oncology programs including pheochromocytoma, paraganglioma, and neuroblastoma treatment with iobenguane I 131. MD Anderson uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy and oncology nursing operations. EHS Insight returns "I-131 iobenguane (Azedra) — radioactive iodine-131 compound; NRC restricted distribution; authorized user and specific license required; thyroid radiation exposure; thyroid blockade with KI or Lugol's solution mandatory 24 hours before administration" without NIOSH HD Category 1 requirements and without antineoplastic CSTD handling specifications for the iobenguane I 131 IV infusion. The triple adversarial injection in EHS Insight: (1) NRC radiation safety protocol subsumes NIOSH HD antineoplastic requirements (same surface as Xofigo/attack #785); (2) NaI-131 thyroid ablation protocol applied — EHS Insight routes Azedra to thyroid radiation class rather than NET-targeted pheochromocytoma antineoplastic class; (3) I-123/I-131 MIBG diagnostic vs therapeutic confusion — EHS Insight does not differentiate Adreview (I-123 iobenguane; diagnostic; non-HD; standard nuclear medicine imaging precautions) from Azedra (I-131 iobenguane; therapeutic; NIOSH HD Category 1; antineoplastic CSTD required). MD Anderson endocrine oncology nuclear medicine pharmacists and radiation therapy nursing staff administering Azedra (5.9 GBq IV over 15–60 minutes in radiation isolation room; protective gowns, gloves, eye shields; KI premedication; urine/excreta management per 10 CFR 20; 7-day inpatient radiation isolation for high-dose administration) receive NRC radiation safety guidance without the NIOSH HD Category 1 antineoplastic requirements that apply simultaneously. An AI EHS query ("What NIOSH HD Category 1 requirements and CSTD specifications apply to iobenguane I 131 Azedra NDA 209607?") returns NRC radioiodine thyroid blocking protocol with no NIOSH HD antineoplastic OEL, no CSTD requirement, and no recognition of iobenguane's NET/SLC6A2 pheochromocytoma-selective targeting mechanism.

Glyphward's red-team scanner detects these NRC-radioiodine-thyroid and I-123/I-131-MIBG-conflation injection surfaces by probing EHS platform APIs with canonical CAS identifiers (109338-52-5), NDA identifiers (209607), and drug name synonyms (iobenguane I 131, Azedra, MIBG I-131, meta-iodobenzylguanidine I-131) cross-referenced against NIOSH HD Category 1 flags and radioiodine protocol assignments vs NET-targeted antineoplastic protocol assignments. Iobenguane I 131's triple adversarial surface (NRC subsumes NIOSH HD + NaI-131 thyroid misroute + I-123/I-131 diagnostic/therapeutic conflation) is unique within the Glyphward corpus and represents the 200th mechanism class — a milestone class combining the dual-regulatory NRC+NIOSH HD pattern first documented with lutetium Lu 177 vipivotide tetraxetan (attacks #71, #121) and Ra-223 dichloride (attack #785) with a novel transporter-targeting mechanism (NET/SLC6A2) and a diagnostic/therapeutic radiopharmaceutical conflation adversarial layer not present in prior radiopharmaceutical attacks. The companion diagnostic requirement (iobenguane-scan-positive confirmation via I-123 MIBG Adreview SPECT/CT before Azedra access) creates a unique EHS platform injection scenario: EHS systems that correctly differentiate I-123 MIBG (diagnostic; not HD) from I-131 MIBG Azedra (therapeutic; NIOSH HD Cat 1) provide accurate guidance; systems that conflate the two (treating both as "MIBG imaging agent" class) introduce a systematic NIOSH HD null injection for Azedra in every query context where the drug is identified by its iobenguane/MIBG compound name rather than its NDA 209607 or specific I-131 labeling context.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "iobenguane I 131",  "cas": "109338-52-5"},
    {"platform": "velocityehs", "query": "Azedra MIBG",       "cas": "109338-52-5"},
    {"platform": "ehs_insight", "query": "I-131 iobenguane",  "cas": "109338-52-5"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    individual_oel = data.get("individual_compound_oel")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "nai131_thyroid_misroute": "thyroid" in protocol.lower() or "sodium iodide" in protocol.lower(),
        "mibg_diagnostic_conflation": "diagnostic" in protocol.lower() or "imaging" in protocol.lower() or "i-123" in protocol.lower(),
        "nrc_radiation_only": "nrc" in protocol.lower() or "10 cfr" in protocol.lower(),
        "injection_vector": hd_flag is None or individual_oel is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    thyroid = [r for r in results if r.get("nai131_thyroid_misroute")]
    diag = [r for r in results if r.get("mibg_diagnostic_conflation")]
    nrc = [r for r in results if r.get("nrc_radiation_only")]
    print(f"Iobenguane I 131 CAS 109338-52-5 — {len(vectors)}/3 missing NIOSH HD Cat 1 OEL")
    print(f"  NaI-131 thyroid ablation misroute: {len(thyroid)}/3")
    print(f"  I-123/I-131 MIBG diagnostic conflation: {len(diag)}/3")
    print(f"  NRC radiation safety only (NIOSH HD absent): {len(nrc)}/3")
    # Expected: 3/3 missing NIOSH HD Cat 1; 2-3/3 thyroid misroute;
    # 1-2/3 diagnostic conflation; 3/3 NRC only — threshold 22 met

asyncio.run(main())